Diabetes area participation analysis: a review of companies and targets described in the 2008 - 2010 patent literature (Q37810292)

23 August 2017

Diabetes area participation analysis: a review of companies and targets described in the 2008 - 2010 patent literature (English)

1 reference

23 August 2017

Philip A Carpino

1

1 reference

PubMed ID

21083519

23 August 2017

Bryan Goodwin

series ordinal

2

1 reference

PubMed ID

21083519

23 August 2017

language of work or name

English

0 references

publication date

1 December 2010

1 reference

Expert Opinion on Therapeutic Patents

23 August 2017

1 reference

23 August 2017

20

1 reference

23 August 2017

12

1 reference

23 August 2017

1627-1651

1 reference

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

It's not how fat you are, it's what you do with it that counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Regulation of plasma triglycerides in insulin resistance and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Economic costs of diabetes in the U.S. In 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Insulin resistance in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

How many drug targets are there?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

AMPK: an emerging drug target for diabetes and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

SIRT1 transgenic mice show phenotypes resembling calorie restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Impact of mitochondrial reactive oxygen species and apoptosis signal-regulating kinase 1 on insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Glucose and fat metabolism in adipose tissue of acetyl-CoA carboxylase 2 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Gene knockout of Acc2 has little effect on body weight, fat mass, or food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Review of recent acetyl-CoA carboxylase inhibitor patents: mid-2007-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

The mechanism by which rat liver glucokinase is inhibited by the regulatory protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Assessing the potential of glucokinase activators in diabetes therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Differential expression and regulation of the glucokinase gene in liver and islets of Langerhans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Glucokinase is the likely mediator of glucosensing in both glucose-excited and glucose-inhibited central neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Glucose sensing in L cells: a primary cell study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Glucokinase and molecular aspects of liver glycogen metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Cell-specific roles of glucokinase in glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Allosteric activators of glucokinase: potential role in diabetes therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

GPR40 is expressed in glucagon producing cells and affects glucagon secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

The long-chain fatty acid receptor, GPR40, and glucolipotoxicity: investigations using GPR40-knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

GPR40: good cop, bad cop?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

GPR119 agonists for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Does central obesity reflect "Cushing's disease of the omentum"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Tissue-specific dysregulation of cortisol metabolism in human obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

A transgenic model of visceral obesity and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

17beta-Hydroxysteroid dehydrogenase inhibitors: a patent review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Stearoyl-CoA desaturase 1 deficiency elevates insulin-signaling components and down-regulates protein-tyrosine phosphatase 1B in muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Stearoyl-CoA desaturase 1 deficiency increases insulin signaling and glycogen accumulation in brown adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Lack of stearoyl-CoA desaturase 1 upregulates basal thermogenesis but causes hypothermia in a cold environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Low hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

11-Beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in Type 2 diabetes mellitus and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.533171

10.1517/13543776.2010.533171

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

21083519